Predictive value of early brain atrophy on response in patients treated with interferon β

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 4, 2015, Pages

  Pérez Miralles, Francisco Carlos ^a,b   Sastre Garriga, Jaume ^a   Vidal Jordana, Angela ^a   Río, Jordi ^a   Auger, Cristina ^a   Pareto, Deborah ^a   Tintoré, Mar ^a   Rovira, Alex ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; MITOXANTRONE;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL OUTCOME; DISABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT RESPONSE; WHITE MATTER;

EID: 84966541996     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000132     Document Type: Article

References (39)

1. Río J., Castilló J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009; 15:848-853. doi:10.1177/1352458509104591.
2. Kobelt G, Berg J, Lindgren P., Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006; 77:918-926. doi:10.1136/jnnp.2006.090365.
3. Bermel RA, You X, Foulds P., et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon b. Ann Neurol 2013; 73:95-103. doi:10.1002/ana.23758.
4. Río J., Nos C, Tintoré M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59:344-352. doi:10.1002/ana.20740.
5. Sormani MP, Arnold DL, de Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2014; 75:43-49. doi:10.1002/ana.24018.
6. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452.
7. McDonald WI, Compston A, Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-127.
8. Rovira A, Tintoré M, Álvarez-Cermeño JC, Izquierdo G, Prieto JM. Recomendaciones para la utilización e interpretación de los estudios de resonancia magnética en la esclerosis múltiple. Neurologia 2010; 25:248-265. doi:10.1016/j.nrl.2010.03.001.
9. Plummer D. Dispimage: a display and analysis tool for medical images. Riv Neuroradiol 1992; 5:1715-1720.
10. Smith SM, Zhang Y, Jenkinson M., et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17:479-489.
11. Smith SM, Jenkinson M, Woolrich M.W., et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004; 23(suppl 1): S208-S219. doi:10.1016/j.neuroimage.2004.07.051.
12. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998; 316:1236-1238.
13. Sormani MP, De Stefano N. Defining and scoring response to IFN-b in multiple sclerosis. Nat Rev Neurol 2013; 9:504-512. doi:10.1038/nrneurol.2013.146.
14. Río J., Rovira A, Tintoré M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsingremitting multiple sclerosis patients. Mult Scler 2008; 14: 479-484. doi:10.1177/1352458507085555.
15. Sormani MP, Río J, Tintoré M, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013; 19:605-612. doi:10.1177/1352458512460605.
16. Pérez-Miralles F., Sastre-Garriga J, Tintoré M, et al. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler 2013; 19:1878-1886. doi:10.1177/1352458513488231.
17. Dalton CM, Chard DT, Davies G.R., et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127:1101-1107. doi:10.1093/brain/awh126.
18. Vrenken H, Jenkinson M, Horsfield M.A., et al. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol 2013; 260:2458-2471. doi:10.1007/s00415-012-6762-5.
19. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006; 5:158-170. doi: 10.1016/S1474-4422(06)70349-0.
20. Zivadinov R, Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 2004; 14(3 suppl):27S-35S. doi:10.1177/1051228404266266.
21. Raz N, Rodrigue KM Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev 2006; 30:730-748. doi:10.1016/j.neubiorev.2006.07.001.
22. Rojas JI, Patrucco L, Miguez J., Besada C, Cristiano E. Brain atrophy as a non-response predictor to interferonbeta in relapsing-remitting multiple sclerosis. Neurol Res 2014; 36:615-618.
23. Kappos L, Freedman MS, Polman C.H., et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370:389-397.
24. De Stefano N., Comi G, Kappos L., et al. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2014; 85: 647-653. doi:10.1136/jnnp-2013-306289.
25. Filippi M, Rovaris M, Inglese M., et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1489-1496. doi:10.1016/S0140-6736(04)17271-1.
26. Rudick RA, Fisher E, Lee J.C., Duda JT, Simon J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 2000; 6:365-372.
27. Zivadinov R, Reder AT, Filippi M, et al Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71:136-144. doi:10.1212/01.WNL.0000316810.01120.05.
28. Hardmeier M, Wagenpfeil S, Freitag P., et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005; 64:236-240. doi:10.1212/01.WNL.0000149516.30155.B8.
29. Geurts JJG, Calabrese M, Fisher E., Rudick RA. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012; 11:1082-1092. doi:10.1016/S1474-4422(12)70230-2.
30. Zivadinov R, Locatelli L, Cookfair D., et al. Interferon beta-1a slows progression of brain atrophy in relapsingremitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 2007; 13:490-501. doi:10.1177/1352458506070446.
31. Wolinsky JS, Narayana PA, Nelson F, et al Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013; 19:1310-1319. doi:10.1177/1352458513475723.
32. Filippi M, Rocca MA, Pagani E, et al Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry 2014; 85:851-858. doi:10.1136/jnnp-2013-306132.
33. Dobson R, Rudick RA, Turner B, Schmierer K., Giovannoni G. Assessing treatment response to interferon-b: is there a role for MRI? Neurology 2014; 82:248-254. doi:10.1212/WNL.0000000000000036.
34. Goodin DS, Traboulsee A, Knappertz V., et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83:282-287. doi:10.1136/jnnp-2011-301178.
35. Battaglini M, Jenkinson M, De Stefano N. Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp 2012; 33:2062-2071. doi:10.1002/hbm.21344.
36. Miller DH, Barkhof F, Frank J.A., Parker GJM, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002; 125:1676-1695.
37. Vidal-Jordana A., Sastre-Garriga J, Pérez-Miralles F, et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 2013; 19: 1175-1181. doi:10.1177/1352458512473190.
38. Miller D, Barkhof F, Montalban X., Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4:281-288. doi:10.1016/S1474-4422(05)70071-5.
39. Durand-Dubief F., Belaroussi B, Armspach J.P., et al. Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques. AJNR Am J Neuroradiol 2012; 33:1918-1924.